Antibody-drug conjugates are also being assessed as neoadjuvant therapy in resectable gastric cancers; examples include the phase II EPOC2003 study, which will examine T-DXd in both HER2 overexpressed and HER2-low disease (NCT05034887) [52] and RC48 with chemo-immunotherapy in HER2-positive resectable gastric cancers (NCT05113459) (Table 2). The gene discussed is ERBB2; the disease is gastric cancer.